Cheapest GLP-1 Cost Comparison 2026

See if you qualify →
5-minute questionnaire · reviewed by a licensed clinician · The Nouri Promise: if you're not satisfied in your first 30 days, you get a full refund — available on 3-month and 6-month plans

At a glance: cheapest GLP-1 cost comparison (2026)

Option	Monthly cost (2026 sticker)	What's included	FDA-approved?
Compounded semaglutide (telehealth)	~$99–$199 + possible membership	Medication; support varies by provider	No
Wegovy oral pill (self-pay)	~$149	Medication only	Yes (weight management)
Compounded tirzepatide (telehealth)	~$125–$399 + possible membership	Medication; support varies by provider	No
Wegovy injection (self-pay)	~$349	Medication only	Yes (weight management)
Ozempic (self-pay)	~$349	Medication only	Yes (type 2 diabetes)
Zepbound vials — LillyDirect	~$299–$449	Medication only	Yes (weight management)
Mounjaro (no self-pay discount program)	~$1,000+	Medication only	Yes (type 2 diabetes)
Nouri — semaglutide, 6-month plan (all-in)	$120/mo ($720 billed)	Compounded medication + nutrition plan + fitness plan + clinician care	No (compounded)
Nouri — semaglutide, 3-month plan (all-in)	$145/mo ($435 billed)	Same as above	No (compounded)
Nouri — tirzepatide, 6-month plan (all-in)	$175/mo ($1,050 billed)	Same as above	No (compounded)
Nouri — tirzepatide, 3-month plan (all-in)	$199/mo ($597 billed)	Same as above	No (compounded)

Brand/competitor prices reflect publicly available information as of June 2026 from manufacturer and pharmacy websites — verify current figures before deciding. Compounded competitor prices are a market range; Nouri prices are exact. See Nouri's GLP-1 telehealth pricing dataset for compiled market data.

Why GLP-1 prices span such a wide range

GLP-1 receptor agonists — semaglutide and tirzepatide are the two active molecules in this class — come from two structurally different supply chains in 2026, and those chains explain most of the price variation.

Brand-name, FDA-approved drugs (Wegovy, Ozempic, Zepbound, Mounjaro) are manufactured by Novo Nordisk and Eli Lilly, sold through retail pharmacies, and listed at prices that often exceed $1,000/month without insurance. Manufacturer self-pay savings programs — NovoCare for Wegovy, LillyDirect for Zepbound — bring those figures down substantially, to approximately $149–$449 depending on the form and program. These drugs went through FDA's full approval process, supported by large clinical trials of the branded molecules: semaglutide's weight-management indication is based on the STEP-1 trial (Wilding et al., NEJM, 2021), tirzepatide's by SURMOUNT-1 (Jastreboff et al., NEJM, 2022). Those trials studied the FDA-approved branded drugs, not compounded versions.

Compounded GLP-1 medications are prepared by state-licensed compounding pharmacies (503A or 503B under federal law) using active pharmaceutical ingredients. They are not FDA-approved, and the FDA does not evaluate compounded products for safety, efficacy, or quality in the same way it does brand-name drugs. They are legal when prescribed by a licensed provider for a patient's individual clinical needs. Because compounding pharmacies source ingredients directly without brand-name R&D recovery costs, the price is substantially lower — but the regulatory protections also differ. FDA's compounding overview explains those differences in detail.

Within the compounded category, prices vary further based on what's included: some programs charge for medication only; others bundle clinician consultations, nutrition coaching, or care coordination — either within the medication price or as a separate mandatory membership.

The membership fee trap: cheapest headline is not cheapest all-in

The most common source of confusion in this market is the gap between the advertised "medication price" and the real monthly cost. Many "$99/month" compounded GLP-1 programs add a separate mandatory membership fee of $49–$79/month covering consultations, messaging, or the care platform. The medication is $99; the total charge to your card is $148–$178.

That is not inherently a bad structure — clinical support and behavioral guidance have real value, especially for a treatment that works best alongside dietary and lifestyle changes. But when comparing programs, you need one number: the all-in monthly cost, including every mandatory recurring charge.

Questions to ask any provider before signing up:

• Is there a separate membership or platform fee? Is it optional or mandatory?
• Is the initial consultation included, or billed separately?
• Does the price change at higher doses, or stay flat?
• Are follow-up clinician check-ins included, or charged per visit?

For a full structural breakdown of what each type of program typically includes, see our guide to compounded vs. brand GLP-1 cost and the overview in our GLP-1 cost guide for 2026.

Brand self-pay options in 2026: what each drug costs

All four brand-name GLP-1 drugs have self-pay mechanisms in 2026, but the programs and prices vary considerably.

Wegovy (semaglutide, FDA-approved for weight management)

Novo Nordisk's NovoCare program offers self-pay pricing for Wegovy. As of June 2026, the Wegovy injection pen is approximately $349/month and an oral form is available at approximately $149/month under the self-pay program. These programs have time-limited introductory pricing — confirm current figures at NovoCare's pricing page before deciding.

Zepbound (tirzepatide, FDA-approved for weight management)

Eli Lilly sells Zepbound vials directly through LillyDirect at tiered prices: approximately $299/month (lower doses) to $449/month (higher doses), as of June 2026. Eligibility conditions apply — verify current tiers at LillyDirect.

Ozempic (semaglutide, FDA-approved for type 2 diabetes)

Ozempic is FDA-approved for type 2 diabetes management, not for weight loss, and is sometimes prescribed off-label for weight management. Without insurance, it typically runs approximately $349/month. Because it lacks an FDA weight-management indication, it is less common in commercial telehealth weight programs. For a full breakdown, see our guide to Ozempic cost without insurance.

Mounjaro (tirzepatide, FDA-approved for type 2 diabetes)

Mounjaro is FDA-approved for type 2 diabetes. Without insurance and without patient-assistance, it typically exceeds $1,000/month — there is no broad self-pay discount program comparable to LillyDirect's Zepbound vials.

For per-drug deep dives: Wegovy cost without insurance · Zepbound cost without insurance · Ozempic cost without insurance.

Compounded GLP-1 programs: what drives the price range

Compounded semaglutide and tirzepatide are available from many telehealth platforms in 2026, with sticker prices ranging from roughly $99 to $399/month. That range reflects real differences in program structure:

• Plan length: Quarterly or semi-annual commitments typically reduce the per-month equivalent versus monthly billing cycles.
• Dose policy: Some providers charge the same price at any dose; others charge more as doses increase during titration. Ask explicitly how the cost changes when your provider adjusts your dose upward.
• What's bundled: Medication only, or medication plus nutrition guidance, fitness programming, and clinical check-ins?
• Pharmacy legitimacy: State-licensed 503A pharmacies prepare medications for individual patients; 503B outsourcing facilities prepare in larger volume batches. Not all telehealth providers name their compounding pharmacy — providers who do are easier to verify.

The FDA has published guidance on the risks of unapproved compounded GLP-1 products, including concerns about products sold without a legitimate prescription or from unverified sources. The NIDDK's overview of prescription obesity medications provides additional context on how these medications are prescribed and what the clinical eligibility criteria typically look like.

For a structured comparison of compounded and brand programs on cost, regulatory status, and access, see: compounded vs. brand GLP-1: a cost comparison. For medication-specific pricing, see semaglutide cost and tirzepatide cost without insurance.

Is cheap always safe? How to evaluate a provider

Markers of a legitimate program include: a real clinical evaluation before prescribing, a named and verifiable state-licensed 503A compounding pharmacy, transparent all-in pricing, and a telehealth certification from an organization like LegitScript, which verifies prescribing practices and pharmacy legitimacy.

Medicare and coverage options in 2026

Most insurance plans — including Medicare Part D — have historically excluded FDA-approved GLP-1 weight-loss drugs from coverage, though this is changing in some markets. Two notable 2026 developments:

• Medicare GLP-1 Bridge program: Starting July 1, 2026, eligible Medicare Part D beneficiaries may access a $50/month GLP-1 medication program through a new CMS initiative. See the CMS press release for current eligibility criteria and the covered drug list — these details may update before the launch date.
• Commercial insurance: Roughly 40% of commercial plans still exclude GLP-1 weight-loss drugs; prior authorization requirements are common among those that do cover them. For guidance on navigating insurance, see our guides: does insurance cover Wegovy and Zepbound? and how to get a GLP-1 covered by insurance.

Compounded GLP-1 programs like Nouri operate outside of insurance, with direct self-pay pricing. There is no insurance billing for Nouri's program.

FSA and HSA reimbursement

Compounded GLP-1 medications prescribed by a licensed provider as part of treatment for obesity or a related medical condition may be eligible for FSA or HSA reimbursement under IRC §213(d) as a qualified medical expense. Whether a specific plan will reimburse depends on the plan's terms — this is not universal. Nouri does not accept FSA/HSA cards directly at checkout; this would be a post-payment reimbursement submitted by the member. Confirm eligibility with your plan administrator and, for any tax question, a qualified tax professional. For a full breakdown, see our guide to using HSA/FSA for a GLP-1.

Where Nouri fits in this cost comparison

Nouri charges one transparent all-in price — no membership layer, no per-dose surcharge, no add-on consultation fees:

• Compounded semaglutide: $120/mo on the 6-month plan ($720 billed every 6 months) · $145/mo on the 3-month plan ($435 billed) · $175/mo billed monthly.
• Compounded tirzepatide: $175/mo on the 6-month plan ($1,050 billed every 6 months) · $199/mo on the 3-month plan ($597 billed) · $225/mo billed monthly.

Every Nouri plan includes compounded medication when prescribed by a U.S.-licensed physician, a personalized nutrition plan, a movement and fitness plan, and ongoing care — at the same price regardless of dose. Nouri is available in all 50 states and is LegitScript-certified. Medication is dispensed by Jungle Jim's Pharmacy, a state-licensed 503A compounding pharmacy in Fairfield, Ohio, and VialsRX.

Compounded GLP-1 medications are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs. Medication is prescribed only when clinically appropriate, after evaluation by a licensed provider. Not all applicants qualify.

Start your 5-minute assessment →
5-minute questionnaire · reviewed by a licensed clinician · The Nouri Promise: if you're not satisfied in your first 30 days, you get a full refund — available on 3-month and 6-month plans · cancel anytime

How to compare GLP-1 programs beyond sticker price

A practical checklist before you choose a program:

1. Get the all-in monthly number. Medication + mandatory membership + consultation + per-dose fees — one figure, not a menu.
2. Confirm the pharmacy is named and verifiable. A legitimate provider names a specific state-licensed 503A or 503B compounding pharmacy you can look up independently.
3. Ask how pricing changes as your dose increases. Some programs charge more at higher doses; others keep the price flat.
4. Understand what support is included. Medication-only programs put the behavioral and nutritional work entirely on you; bundled programs provide clinical guidance throughout.
5. Read the refund and cancellation terms. A legitimate program with a money-back guarantee states the material terms clearly — duration, eligibility, and how to claim.
6. Check for independent certification. LegitScript and similar certifications require verification of prescribing practices and pharmacy legitimacy; they are a meaningful signal of accountability.

For a current view of what programs across the telehealth market charge, see Nouri's GLP-1 telehealth pricing dataset on HuggingFace, which compiles publicly available pricing across providers. Our full GLP-1 cost guide for 2026 has the complete landscape.

Related cost guides

• GLP-1 cost guide 2026 (full overview)
• Compounded vs. brand GLP-1 cost
• Semaglutide cost (with and without insurance)
• Tirzepatide cost without insurance
• Ozempic cost without insurance
• Wegovy cost without insurance
• Zepbound cost without insurance
• Can you use HSA/FSA for a GLP-1?

Frequently asked questions

What's the cheapest GLP-1 without insurance?

On sticker price, compounded semaglutide (~$99–$199/month) and the Wegovy oral pill (~$149) are typically the lowest-cost routes. Brand self-pay options run ~$299–$449 (Zepbound vials) and ~$349 (Wegovy injection). Always verify the all-in monthly cost — including any mandatory membership fee. Compounded GLP-1 medications are not FDA-approved.

What's the cheapest way to get semaglutide online?

Compounded semaglutide through a telehealth provider carries the lowest sticker price (~$99–$199/month), but many programs add a $49–$79 monthly membership on top. Brand self-pay (Wegovy ~$349 injection, ~$149 oral) is the FDA-approved route. Compounded semaglutide is not FDA-approved and not therapeutically equivalent to Wegovy or Ozempic. Compare all-in costs before choosing.

Which GLP-1 is cheapest — Ozempic, Wegovy, Zepbound, or compounded?

At self-pay rates: Wegovy injection and Ozempic are approximately $349/month, Zepbound vials $299–$449, Mounjaro $1,000+ with no broad cash discount program. Compounded semaglutide (~$99–$199 sticker) and tirzepatide (~$125–$399 sticker) are often lower on sticker price, but are not FDA-approved and the real all-in cost varies based on mandatory membership fees.

Is it safe to buy a GLP-1 online?

From a legitimate telehealth provider, yes. A legitimate program requires a clinician evaluation, names a state-licensed 503A or 503B pharmacy, and shows transparent pricing. The FDA has warned about counterfeit and adulterated compounded GLP-1 products. Avoid any provider that ships without a prescription, won't name their pharmacy, or claims their compounded product is FDA-approved or equivalent to a brand-name drug.

Does FSA or HSA cover compounded GLP-1?

Compounded GLP-1 medications prescribed for a qualifying medical condition may be eligible for FSA or HSA reimbursement under IRC §213(d). Eligibility depends on your specific plan. Nouri does not accept FSA/HSA cards directly — this would be post-payment reimbursement. Confirm with your plan administrator and a qualified tax professional before submitting a claim.

How low will GLP-1 prices go in 2026?

Brand self-pay prices have declined to approximately $149–$449/month depending on the drug and dosage form. A new $50/month Medicare GLP-1 Bridge program is expected to begin July 1, 2026, for eligible Medicare beneficiaries. There is no U.S. generic for semaglutide or tirzepatide yet; significant retail price drops are not expected until after patent expiration, currently projected around 2032.

Sources & references

1. FDA: Human Drug Compounding — regulatory framework for 503A and 503B compounding pharmacies (U.S. Food & Drug Administration).
2. FDA: Postmarket Drug Safety — GLP-1 unapproved product concerns — FDA warnings on compounded GLP-1 products sold without a valid prescription or from unverified sources.
3. NIDDK: Prescription medications to treat overweight and obesity — National Institute of Diabetes and Digestive and Kidney Diseases overview of approved weight-management medications.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM, 2021. — Registration trial of semaglutide (the active molecule in Wegovy) for weight management in adults; not a study of compounded semaglutide.
5. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM, 2022. — Registration trial of tirzepatide (the active molecule in Zepbound) for weight management in adults; not a study of compounded tirzepatide.
6. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM, 2023. — Cardiovascular outcomes trial of branded semaglutide in adults with obesity and established cardiovascular disease.
7. Wegovy self-pay pricing — NovoCare (as of June 2026). Re-verify before publishing.
8. Zepbound self-pay vials — LillyDirect (as of June 2026). Re-verify before publishing.
9. CMS: $50/month Medicare GLP-1 Bridge program (July 2026).
10. GoodRx: GLP-1 drug cost and savings guide (2026).
11. Nouri GLP-1 telehealth pricing dataset (HuggingFace, 2026) — compiled public pricing across GLP-1 telehealth providers.

Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as pricing and regulatory guidance change.

Prices and coverage information described here reflect publicly available data as of June 2026 and change frequently — re-verify current figures with the manufacturer, your pharmacy, your insurer, and (for HSA/FSA or tax questions) a qualified tax professional before making any decisions. This content is for general informational purposes only and does not constitute medical, financial, or tax advice. The clinical trial data cited (STEP-1, SURMOUNT-1, SELECT) are studies of FDA-approved branded molecules — Wegovy, Zepbound — and are not evidence of outcomes for Nouri's compounded medications or for any individual patient. Brand registrations: Ozempic®, Wegovy®, and Rybelsus® are trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. Nouri is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs. Medication is prescribed only when clinically appropriate, after evaluation by a licensed provider. Not all applicants qualify. Individual results vary.